IAVI

Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

IAVI Report

The future of mRNA-based HIV vaccines is about more than speed

April 27, 2022

Right now in vaccine research, mRNA has the momentum. For HIV, there are currently several formulations of experimental vaccines in early-stage human clinical trials. Apart from some overlap in strategy, they have one main thing in common — they rely on mRNA. This trend reflects the intense overall interest in mRNA-based vaccine development, given its…

Read more

IAVI Report

Jon Cohen on writing about COVID-19 and why we must prepare now for the next public health crisis

April 27, 2022

A conversation with Jon Cohen about what made writing about this pandemic different and what stories are still to be told.

Read more

Scientific Publications

Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia

Read more

Scientific Publications

Evaluating the effectiveness of enhanced family planning education on knowledge and use of family planning in fishing communities of Lake Victoria in Uganda: a randomized controlled trial

Read more

Press Releases

IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies

April 7, 2022

Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis.

Read more

Scientific Publications

Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans

Read more

Videos

A new approach to HIV vaccination

March 17, 2022

Watch this educational video to learn more about HIV bnAbs, sequential immunization, and IAVI's exciting new approach to HIV vaccine design. Broadly neutralizing antibodies, bnAbs for short, have the potential to neutralize or prevent infection with, many different HIV strains. IAVI’s goal is to design a series of sequential vaccine candidates that will prepare B cells to produce bnAbs before a person is exposed to HIV. These bnAbs could then protect the person from acquiring HIV if they were exposed to the virus in the future.  We are eager to continue our work developing a safe, effective HIV vaccine, which the world needs.

Read more

Features

HVTN 302 begins first dosing of mRNA HIV vaccine antigens

March 17, 2022

HVTN, NIAID, and Moderna partner on trial of HIV Env trimers designed by IAVI's William Schief.

Read more